(2022). Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. New England Journal of Medicine, 387(13), 1161–1172. https://doi.org/10.1056/nejmoa2205225

Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., Andrews, J. A., Babu, S., Benatar, M., McDermott, C. J., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., … Fradette, S. (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387(12), 1099–1110. https://doi.org/10.1056/nejmoa2204705

Montgomery, R. A., Stern, J. M., Lonze, B. E., Tatapudi, V. S., Mangiola, M., Wu, M., Weldon, E., Lawson, N., Deterville, C., Dieter, R. A., Sullivan, B., Boulton, G., Parent, B., Piper, G., Sommer, P., Cawthon, S., Duggan, E., Ayares, D., Dandro, A., … Stewart, Z. A. (2022). Results of Two Cases of Pig-to-Human Kidney Xenotransplantation. New England Journal of Medicine, 386(20), 1889–1898. https://doi.org/10.1056/nejmoa2120238

Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., Miller, A., Zhang, X., Lynch, J., Kim, D., Ribeil, J.-A., Asmal, M., Goyal, S., Thompson, A. A., & Tisdale, J. F. (2022). Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 386(7), 617–628. https://doi.org/10.1056/nejmoa2117175

Fink, G., Mrema, S., Abdulla, S., Kachur, S. P., Khatib, R., Lengeler, C., Masanja, H., Okumu, F., & Schellenberg, J. (2022). Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania. New England Journal of Medicine, 386(5), 428–436. https://doi.org/10.1056/nejmoa2112524

Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., … Gonzalez-Lopez, A. (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine, 385(25), 2348–2360. https://doi.org/10.1056/nejmoa2105290